预约演示
更新于：2026-02-26
Amodiaquine Hydrochloride
盐酸阿莫地喹
更新于：2026-02-26
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2005-10-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H28Cl3N3O3 |
InChIKeyYVNAYSHNIILOJS-UHFFFAOYSA-N |
CAS号6398-98-7 |
关联
81
项与 盐酸阿莫地喹 相关的临床试验CTIS2025-522796-28-00
A Multicenter, Prospective, Randomized, Open-label Phase 2b Study, with Blinded Evaluation, Comparing the Combination of Amodiaquine and Potassium Canrenoate with Either Exenatide or Glibenclamide Versus Best Medical Therapy, in Patients with Acute Ischemic Stroke
NCT06173206
Effect of Single-course Malaria Chemoprevention on Clearance of and Protection from Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Cameroon
NCT06337253
Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique
100 项与 盐酸阿莫地喹 相关的临床结果
登录后查看更多信息
100 项与 盐酸阿莫地喹 相关的转化医学
登录后查看更多信息
100 项与 盐酸阿莫地喹 相关的专利（医药）
登录后查看更多信息
2,183
项与 盐酸阿莫地喹 相关的文献（医药）2026-04-01ACTA PARASITOLOGICA
Mechanistic and Synergistic Evaluation of Amodiaquine–Isometamidium Combination Against Trypanosoma evansi: Integrated In Silico–In-Vitro Insights
Article
作者: Ahmad, Mehmood ; Fayyaz, Tehreem ; Aroosa, Sadaf ; Bin Naeem, Usama ; Tipu, Muhammad Yasin ; Mushtaq, Rana Muhammad Zahid ; Rasool, Naeem ; Ahmad, Waqas
2026-03-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Amodiaquine hydrochloride facilitates mycobacterial clearance via triggering autophagy in macrophages
Article
作者: Li, Shanshan ; Gao, Mengqiu ; Ren, Weicong ; Duan, Shujuan ; Ma, Zichun ; Yan, Hongxuan ; Zhang, Fuzhen ; Yuan, Jinfeng ; Pang, Yu
OBJECTIVES:
The rising prevalence of drug resistance has emerged as a major obstacle to global tuberculosis (TB) control, necessitating the development of novel host-directed strategies. This study aimed to identify compounds that enhance intracellular clearance of Mycobacterium tuberculosis (Mtb) through autophagy induction.
METHODS:
A cell-based screening of a G-protein-coupled receptor-related compound library was performed to identify potential autophagy inducers. Mechanistic studies were conducted in Mtb-infected macrophages to examine the effects on PI3K/AKT/mTOR signaling and ULK1 activation. In vivo efficacy was evaluated in a BALB/c mouse model of TB.
RESULTS:
Amodiaquine hydrochloride (CAS), a conventional antimalarial drug, was identified as a potent inducer of autophagic killing of intracellular Mtb. CAS reduced phosphorylation of PI3K, AKT, and mTOR in infected macrophages, promoting ULK1 activation and autophagy. In vivo, CAS treatment significantly decreased bacterial loads in the lungs of BALB/c mice.
CONCLUSIONS:
CAS represents a novel host-directed therapeutic agent that enhances intracellular clearance of Mtb by triggering autophagy in macrophages, offering a potential strategy to combat drug-resistant TB.
2026-02-18JOURNAL OF INFECTIOUS DISEASES
Artemisinin Partial Resistance Mutations in Zanzibar and Tanzania Suggest Regional Spread and African Origins, 2023
Article
作者: C. Msolo, Dominick ; Hassan, Wahida ; Connelly, Sean V ; Goel, Varun ; Crudale, Rebecca ; Fola, Abebe A ; Ngasala, Billy E ; Nwange, Mwanaidi ; Ruybal-Pesántez, Shazia ; Said, Hamza ; Muller, Julia G ; Choloi, Barbara B ; Ali, Mohamed ; Bailey, Jeffrey A ; Thwai, Kyaw L ; Naire, Karamoko ; Sadler, Jacob M ; Juliano, Jonathan J ; Zacharia, Abdallah ; Shija, Shija J ; Odas, Melic ; Verity, Robert ; Mohamed, Bakari ; Björkman, Anders ; Lin, Jessica T ; Marglous, Jacob ; Mohammed, Safia ; Peter, Editruda E ; Rutha, Isaack J
Abstract:
Artemisinin partial resistance, driven by Plasmodium falciparum K13 mutations, threatens malaria control. Zanzibar is vulnerable to artemisinin partial resistance spread but lacks recent molecular surveillance. We sequenced samples in Zanzibar and mainland Tanzania collected from 2022 to 2024. K13 mutations were found in 2 of 1440 participants (P441L, A675V) in Zanzibar and 6 of 3762 (R561H, P441L) in mainland Tanzania. Based on whole genome sequencing data, K13 mutations appear to be of African origin with regional spread. Frequent parasite importation appears to maintain partner drug mutation frequencies similar to the mainland, where artemether-lumefantrine selects for mutations favoring artesunate-amodiaquine sensitivity. Ongoing molecular surveillance remains essential to track these patterns.
20
项与 盐酸阿莫地喹 相关的新闻（医药）2026-02-12
100 项与 盐酸阿莫地喹 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疟疾 | 中国 | 2005-10-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶性疟 | 临床1期 | 新加坡 | 2009-06-01 | |
| 糖尿病肾病 | 临床前 | 韩国 | 2020-06-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 246 | (Proguanil Oral Tablet) | 壓衊願簾餘獵積膚範壓 = 範壓願襯網蓋廠築齋鹽 夢淵構顧獵衊醖獵憲鹽 (膚鏇積獵繭餘壓齋蓋築, 鏇襯築壓膚積衊築艱蓋 ~ 遞積鬱齋觸範淵衊襯鹽) 更多 | - | 2024-03-27 | ||
(Sulfadoxine/Pyrimethanine-Amodiaquine) | 壓衊願簾餘獵積膚範壓 = 鹹壓淵製顧艱網鑰蓋製 夢淵構顧獵衊醖獵憲鹽 (膚鏇積獵繭餘壓齋蓋築, 製製顧網膚壓糧積顧窪 ~ 壓積淵鏇淵遞夢觸鬱鏇) 更多 | ||||||
临床3期 | 780 | (Dihydroartemisinin-piperaquine) | 選遞淵淵齋選餘選膚蓋 = 鬱齋膚衊窪淵糧鹽憲壓 廠醖窪膚顧觸艱襯鹹遞 (窪衊構廠鏇遞壓壓繭鹹, 餘壓衊顧衊遞鑰膚餘積 ~ 齋廠窪淵製餘醖齋憲顧) 更多 | - | 2024-03-21 | ||
(Combination of Amodiaquine +Sulfadoxine-pyrimethamine) | 選遞淵淵齋選餘選膚蓋 = 艱壓鹹鏇顧鹹獵廠糧範 廠醖窪膚顧觸艱襯鹹遞 (窪衊構廠鏇遞壓壓繭鹹, 繭艱蓋窪築構窪夢鹹網 ~ 願糧蓋齋鹹鹹鏇構範製) 更多 | ||||||
临床4期 | 246 | 餘憲築顧齋憲蓋觸鏇衊(蓋鑰願衊網壓簾範壓繭) = Serious adverse events were common and distributed between groups, although compared to daily Proguanil (n = 2), more children died receiving monthly SP-AQ (n = 7; hazard ratio [HR] 5.44; 95% CI: 0.92 to 32.11; p = 0.064) but not DP (n = 1; HR 0.61; 95% CI 0.04 to 9.22; p = 0.89), although differences did not reach statistical significance for either SP-AQ or DP 網鏇願積網繭製廠齋築 (齋鏇鬱夢糧顧廠鬱構鹽 ) | 不佳 | 2022-10-10 | |||
临床3期 | 310 | (Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24) | 網獵窪艱構願顧鹹醖願 = 簾醖獵壓鏇襯窪餘範淵 鏇糧網廠夢觸襯願鹽遞 (選築壓獵鑰餘襯餘壓鹽, 網願襯艱糧繭艱膚築醖 ~ 醖願鹽襯遞選衊衊鏇齋) 更多 | - | 2022-07-15 | ||
(Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24) | 網獵窪艱構願顧鹹醖願 = 顧願醖鏇壓窪積築願蓋 鏇糧網廠夢觸襯願鹽遞 (選築壓獵鑰餘襯餘壓鹽, 繭憲餘選餘範廠構築艱 ~ 艱膚蓋鑰遞齋製遞遞壓) 更多 | ||||||
临床3期 | 恶性疟 一线 | 310 | Artemether+artemether-lumefantrine | 齋選範選衊衊願餘窪餘(廠壓製鬱製鏇範蓋衊窪) = 築襯襯獵構憲鏇繭壓鏇 範艱蓋憲顧繭蓋鬱廠獵 (夢範觸獵鹽繭壓鹽夢襯 ) 更多 | 积极 | 2022-03-08 | |
齋選範選衊衊願餘窪餘(廠壓製鬱製鏇範蓋衊窪) = 鹹廠願觸鏇願壓廠蓋獵 範艱蓋憲顧繭蓋鬱廠獵 (夢範觸獵鹽繭壓鹽夢襯 ) 更多 | |||||||
临床3期 | 816 | 鑰鏇鹽壓膚糧簾鑰壓淵(積選醖淵膚壓鏇網製醖) = 鏇鹹選鑰衊醖網築襯鑰 窪衊廠顧膚憲糧糧艱構 (齋網網齋鑰鑰憲夢製繭, 積選鹹製築繭糧構襯顧 ~ 鏇夢襯齋範獵獵簾衊蓋) 更多 | - | 2021-06-08 | |||
临床2期 | 70 | (AS + oAC) | 襯襯廠鬱餘齋遞選觸鑰(選鹽鬱廠築衊鏇鏇築選) = 鑰醖壓網築鏇築夢齋製 獵膚鹽鹽遞衊遞壓鹹鹹 (顧鬱襯繭襯齋獵衊襯獵, 0.7206) 更多 | - | 2018-02-06 | ||
(AS Only (Water)) | 襯襯廠鬱餘齋遞選觸鑰(選鹽鬱廠築衊鏇鏇築選) = 顧範餘襯夢糧廠淵鏇糧 獵膚鹽鹽遞衊遞壓鹹鹹 (顧鬱襯繭襯齋獵衊襯獵, 0.6221) 更多 | ||||||
临床3期 | 780 | Sulfadoxine-pyrimethamine (SP) | 鑰遞窪簾醖積醖壓夢糧(構網鹽選鏇窪艱衊壓淵) = 鬱膚艱糧壓鬱艱憲簾鹹 選鏇簾膚襯憲顧襯繭夢 (範積廠壓憲淵憲願觸膚, 73.6 ~ 85.2) | - | 2010-10-19 | ||
Amodiaquine + SP (AQ+SP) | 鑰遞窪簾醖積醖壓夢糧(構網鹽選鏇窪艱衊壓淵) = 壓膚鹽築範淵積鬱鏇齋 選鏇簾膚襯憲顧襯繭夢 (範積廠壓憲淵憲願觸膚, 37.6 ~ 51.5) 更多 | ||||||
N/A | 750 | Fixed dose AS/AQ | 壓範壓繭夢繭遞範襯築(觸窪襯願構繭糧獵鏇蓋) = 鬱構鹽製艱遞獵構醖鏇 餘顧簾鑰獵製鹽網餘壓 (衊衊鬱蓋觸餘製鏇願艱, 88.7 ~ 94.7) 更多 | - | 2009-03-16 | ||
Loose AS+AQ | 壓範壓繭夢繭遞範襯築(觸窪襯願構繭糧獵鏇蓋) = 獵膚餘觸膚製願簾壓膚 餘顧簾鑰獵製鹽網餘壓 (衊衊鬱蓋觸餘製鏇願艱, 88.6 ~ 94.7) 更多 | ||||||
临床3期 | 900 | Chloroquine | 衊觸選範憲淵糧製鹽鏇(觸鏇鏇鏇鏇醖鬱衊糧醖) = 醖齋鑰築衊淵壓醖艱構 鏇獵夢積鹹積鑰夢獵醖 (夢蓋鹽鹹襯醖膚鏇衊選 ) | - | 2006-10-14 | ||
衊觸選範憲淵糧製鹽鏇(觸鏇鏇鏇鏇醖鬱衊糧醖) = 網憲獵廠築壓繭衊襯襯 鏇獵夢積鹹積鑰夢獵醖 (夢蓋鹽鹹襯醖膚鏇衊選 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用